We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Your guide to a disrupted world
Add this topic to your myFT Digest for news straight to your inbox
Revenue rises 60% as Alexion acquisition and its rare diseases medicines boost drugmaker’s earnings
Shares slide as London-listed group announces ‘pause’ in vaccine manufacturing
New therapies replace a blunderbuss with a stiletto
UK drugmaker’s R&D chief says abandoning market would have little impact
UK pharmaceuticals group raises dividend for first time in a decade
Asset managers call for pharma executive pay to be linked to equitable distribution of jabs
The apparent efficacy of its booster against Omicron could shore up the jab’s shaky position among competitors
Pharma group says it is confident its Covid vaccine ‘should be given as a third dose booster’
Global health authorities have voiced concern that current jabs may afford less protection against variant
Protection against severe disease begins to wane three months after second shot
Research shows mRNA vaccines from Pfizer and Moderna are by far most effective third doses
Chief executive says more data needed to explain Europe’s higher rate of admissions
Chair of pharma group says support will boost economy as it opens £1bn R&D campus in Cambridge
British drugmaker’s exclusion from booster campaign is latest setback
Pharma group partnership with Oxford university hits 2bn-dose milestone
Pharma group to move away from non-profit model used during pandemic
Move comes despite Anglo-Swedish group’s non-profit Covid-19 jab suffering setbacks earlier this year
Researchers emphasise that adverse events following Pfizer and AstraZeneca jabs are extremely rare
Vintage legal loophole comes back to haunt drugmaker; City crypto converts in demand; and COP26 takes to the water
Trial results come month after UK terminated contract with French company
Clearly, enough shareholders must accept lowball offers to make the effort worthwhile
Advances by Merck and AstraZeneca raise hopes of bringing more treatments to market
UK pharma group to commercialise 26 drug targets using technology proved by Covid vaccines
Government officials say using different jabs for third doses should provide better protection
International Edition
